Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer

NCT03262454 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT03262454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Unknown status
Start date
January 22, 2018
Completion date
July 31, 2024
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer recurrent